Answers are grounded in this paper and cite their sources.
Preclinical study reveals therapeutic noncoding RNAs enhance phenylalanine metabolism in mice, suggesting novel RNA-based treatments for phenylketonuria.
RNA solution for a genetic problem Phenylketonuria provides a classic case of the benefit of newborn metabolic screening: It is a single-gene disease that can be detected at birth, and its neurological effects can be prevented by dietary therapy. Unfortunately, this is not always straightforward because the disease-causing mutations in phenylalanine hydroxylase vary between patients and affect the severity of the phenotype, such that some patients’ symptoms do not fully respond to the available interventions. Li et al . identified two long noncoding RNAs, one in mice and one in humans, that interact with phenylalanine hydroxylase and modulate its function (see the Perspective by Ben-Tov Perry and Ulitsky). Administration of modified RNAs mimicking their effects ameliorated the disease phenotype in mouse models of phenylketonuria. —YN
No takes yet. Share an insight, caveat, or question.
Li et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: